X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DR. REDDYS LAB - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DR. REDDYS LAB GLENMARK PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 13.7 27.9 49.1% View Chart
P/BV x 3.8 2.9 133.6% View Chart
Dividend Yield % 0.3 1.0 33.6%  

Financials

 GLENMARK PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
DR. REDDYS LAB
Mar-16
GLENMARK PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,2624,383 28.8%   
Low Rs6722,750 24.4%   
Sales per share (Unadj.) Rs270.6920.1 29.4%  
Earnings per share (Unadj.) Rs24.9126.1 19.7%  
Cash flow per share (Unadj.) Rs34.4183.0 18.8%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.20.6 36.9%  
Book value per share (Unadj.) Rs151.3685.8 22.1%  
Shares outstanding (eoy) m282.16170.61 165.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.63.9 92.2%   
Avg P/E ratio x38.928.3 137.4%  
P/CF ratio (eoy) x28.119.5 144.1%  
Price / Book Value ratio x6.45.2 122.8%  
Dividend payout %8.015.9 50.7%   
Avg Mkt Cap Rs m272,778608,481 44.8%   
No. of employees `00010.021.7 46.3%   
Total wages/salary Rs m13,78231,874 43.2%   
Avg. sales/employee Rs Th7,614.97,244.4 105.1%   
Avg. wages/employee Rs Th1,374.81,470.9 93.5%   
Avg. net profit/employee Rs Th700.2992.8 70.5%   
INCOME DATA
Net Sales Rs m76,340156,978 48.6%  
Other income Rs m3562,693 13.2%   
Total revenues Rs m76,696159,671 48.0%   
Gross profit Rs m14,17234,587 41.0%  
Depreciation Rs m2,6919,705 27.7%   
Interest Rs m1,789824 217.1%   
Profit before tax Rs m10,04826,751 37.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,0285,237 57.8%   
Profit after tax Rs m7,01921,514 32.6%  
Gross profit margin %18.622.0 84.3%  
Effective tax rate %30.119.6 154.0%   
Net profit margin %9.213.7 67.1%  
BALANCE SHEET DATA
Current assets Rs m59,096118,201 50.0%   
Current liabilities Rs m40,01868,368 58.5%   
Net working cap to sales %25.031.7 78.7%  
Current ratio x1.51.7 85.4%  
Inventory Days Days7560 125.0%  
Debtors Days Days11997 123.0%  
Net fixed assets Rs m39,07572,265 54.1%   
Share capital Rs m282853 33.1%   
"Free" reserves Rs m30,281111,548 27.1%   
Net worth Rs m42,703117,009 36.5%   
Long term debt Rs m24,87310,690 232.7%   
Total assets Rs m111,026200,104 55.5%  
Interest coverage x6.633.5 19.8%   
Debt to equity ratio x0.60.1 637.6%  
Sales to assets ratio x0.70.8 87.6%   
Return on assets %7.911.2 71.1%  
Return on equity %16.418.4 89.4%  
Return on capital %17.521.6 81.1%  
Exports to sales %43.346.3 93.6%   
Imports to sales %7.49.0 83.0%   
Exports (fob) Rs m33,04472,618 45.5%   
Imports (cif) Rs m5,67214,050 40.4%   
Fx inflow Rs m36,94575,405 49.0%   
Fx outflow Rs m61,06627,115 225.2%   
Net fx Rs m-24,12248,290 -50.0%   
CASH FLOW
From Operations Rs m3,44940,476 8.5%  
From Investments Rs m-8,802-19,421 45.3%  
From Financial Activity Rs m6,986-17,009 -41.1%  
Net Cashflow Rs m9344,046 23.1%  

Share Holding

Indian Promoters % 48.3 25.5 189.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.4 127.8%  
FIIs % 34.4 35.3 97.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.5 15.3 68.6%  
Shareholders   56,727 75,885 74.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty & Pharma Stocks Lead(09:30 am)

Asian stock indices are trading mixed today. The Shanghai Composite is lower by 0.29% while the Hang Seng is even. The Nikkei 225 is trading higher by 0.46%.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 23, 2017 10:39 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - IPCA LABS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS